Overview

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

Status:
Active, not recruiting
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita. This study includes four-parts, and if a participant completes all parts, the participant will have received at least 3-months of PTX-022 treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Palvella Therapeutics, Inc.